MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

They also have strong dividend track records. Apple and Amgen have lagged the market over the trailing-12-month period, but ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.